Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease
about
Targeting Advanced Glycation End Products in Cardiac Surgery: The Unexplored Alternative.Metabolomics in diabetic complications.Antioxidant, antiglycation and insulinotrophic properties of Coccinia grandis (L.) in vitro: Possible role in prevention of diabetic complications.The Association between Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance T1 Mapping and Myocardial Dysfunction in Diabetic Rabbits.Cells and extracellular matrix interplay in cardiac valve disease: because age matters.Computational approaches in the rational design of improved carbonyl quenchers: focus on histidine containing dipeptides.Cellular mechanisms and consequences of glycation in atherosclerosis and obesity.Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.Highlighting Diabetes Mellitus: The Epidemic Continues.Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease.Salidroside Protects Against Advanced Glycation End Products-Induced Vascular Endothelial Dysfunction.Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism.Advanced glycation end products (AGEs) estimated by skin autofluorescence are related with cardiovascular risk in renal transplant
P2860
Q36587374-0882420A-ADC1-4F2F-AFBC-D25BD3703C83Q37041169-B9EF9502-1234-4D75-9074-30BAA8EDC866Q37544053-10818EE5-55FF-4112-87E4-B3C82BF06655Q37719438-746FC6C4-F174-4981-8928-E7478DDADF60Q38718100-EB646B5F-3FF0-4CC1-8B8B-2AC9232FB89BQ38825427-4334320F-7493-4EC0-8A5A-D1EF9A1C30DEQ38831558-A9975712-F9F0-4B1E-B713-0D58C9ACA8CCQ38859313-706A1787-643F-40F1-A82E-6D9745511641Q49547709-B0213A8F-687D-4093-A7D2-C64E20365256Q49833824-40F4EA8A-5C90-416C-8007-47A9B9205EEAQ52373049-639D44A0-4A99-4397-8DDD-1F93A8134B48Q52573088-65EF9009-7C03-4573-ACAE-E4EDE3FB3104Q55262583-D19EFF1B-E1CF-47A7-9DF6-68F6411BB7ADQ56243541-41DD8F36-0ED1-4D1E-9417-64FE18C4BC3C
P2860
Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@ast
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@en
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@nl
type
label
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@ast
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@en
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@nl
prefLabel
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@ast
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@en
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@nl
P2093
P2860
P1476
Pharmacologic Approaches Again ...... iabetic Cardiovascular Disease
@en
P2093
Cristiano Spadaccio
Francesco Nappi
Fraser W Sutherland
Massimo Chello
Sanjeet Singh Avtaar Singh
P2860
P304
P356
10.5812/CARDIOVASCMED.4(2)2015.26949
P407
P577
2015-05-23T00:00:00Z